Who are AR101 - Peanut protein capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Multi-Allergen Oral Immunotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ar101-peanut-protein-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

AR101 - Peanut protein capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AR101 - Peanut protein capsule (AR101 - Peanut protein capsule) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oral immunotherapy. Area: Immunology.

phase 2 oral immunotherapy Immunology Biologic Live · refreshed every 30 min

Target snapshot

AR101 - Peanut protein capsule (AR101 - Peanut protein capsule) — Aimmune Therapeutics, Inc.. AR101 works by desensitizing the immune system to peanut protein, allowing individuals with peanut allergies to safely consume peanuts.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AR101 - Peanut protein capsule TARGET	AR101 - Peanut protein capsule	Aimmune Therapeutics, Inc.	phase 2	oral immunotherapy
Multi-Allergen Oral Immunotherapy	Multi-Allergen Oral Immunotherapy	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Oral immunotherapy (OIT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oral immunotherapy class)

Aimmune Therapeutics, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AR101 - Peanut protein capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/ar101-peanut-protein-capsule. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab